Physician profile
Patrick J Bertolini
NPI 1750330189
$2,548.76
in general payments reported to CMS, 2019-2025
28 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.41 · 2021: $303 · 2022: $602 · 2023: $692 · 2024: $522 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,110.35 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $218.63 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $169.96 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $153.48 | 2023-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $141.80 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $122.82 | 2021-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.99 | 2021-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $66.90 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $55.93 | 2023-2025 | Uptravi, Opsumit |
| Boston Scientific Corporation | $47.85 | 2025 | General - Pain Management |
| Axsome Therapeutics, INC. | $40.53 | 2024 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.12 | 2024 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $30.52 | 2022-2023 | Quviviq |
| Azurity Pharmaceuticals, INC. | $29.96 | 2023 | Horizant |
| Kowa Pharmaceuticals America, INC. | $27.72 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.57 | 2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $23.16 | 2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $19.76 | 2021 | |
| Esperion Therapeutics, INC. | $19.43 | 2023 | Nexletol |
| Pfizer INC. | $19.01 | 2025 | |
| Sanofi Pasteur INC. | $17.41 | 2023 | |
| Dexcom, INC. | $17.18 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.90 | 2025 | Eliquis |
| Amgen INC. | $15.30 | 2024 | Evenity, Prolia |
| Neos Therapeutics, Lp | $15.08 | 2024 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $13.72 | 2021 | |
| Medtronic, INC. | $13.55 | 2023 | Kyphon Express II Kyphopak Tray |
| Exact Sciences Corporation | $13.13 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Bertolini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.